DEF: Tango Therapeutics 2026 Annual Meeting Proxy Statement

Tango Therapeutics has scheduled its 2026 Annual Meeting of Stockholders for June 4, 2026, to elect directors, ratify auditors, and conduct an advisory vote on executive compensation.

Summary

• The 2026 Annual Meeting of Stockholders will be held virtually on June 4, 2026, at 9:00 a.m. Eastern Time.
• Stockholders will vote on the election of three Class II Directors: Malte Peters, M.D., Kanishka Pothula, and Mace Rothenberg, M.D.
• The meeting includes a proposal to ratify PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026.
• An advisory, non-binding vote on the compensation of named executive officers (Say-on-Pay) is included.
• The record date for voting is April 7, 2026, with 144,242,271 shares of common stock outstanding and entitled to vote.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a stable, routine governance filing that highlights successful clinical progress and strong cash positioning, though it remains a pre-commercial company with inherent development risks.

Positives

• Reported positive data from the Phase 1/2 clinical trial of vopimetostat in October 2025, showing durable clinical activity.
• Successfully completed a $225 million financing in October 2025, extending operational runway into 2028.
• Initiated Phase 1/2 trials for vopimetostat in combination with RAS inhibitors and for TNG456 in patients with MTAP-deleted solid tumors.
• Maintained strong fiscal discipline by meeting 2025 budget targets.

Negatives

• Voluntary employee turnover rate was slightly above the goal set by the board of directors in 2025.
• The company reported a net loss of $101.6 million for the 2025 fiscal year.

Risks

• Clinical development risks, including the potential for future trials to fail to meet safety or efficacy endpoints.
• Risks associated with the competitive landscape in oncology drug development.
• Potential for future capital requirements if clinical development timelines or costs exceed current estimates.
• Dependence on key personnel and the challenge of retaining talent in a competitive market.

Future Outlook

The company plans to initiate a pivotal study in second-line pancreatic cancer for vopimetostat in 2026 and provide safety and efficacy updates for its combination trials and TNG456 study in 2026.

Management Comments

• We believe our approach will provide the ability to deliver deep, durable target inhibition with favorable tolerability and safety profiles.
• We are encouraged by the early efficacy signals and safety profile emerging from this study and plan to provide a safety and efficacy update for this study in 2026.

Industry Context

StockSavvy.ai notes that Tango Therapeutics is operating within a highly competitive precision oncology space, where success is heavily dependent on clinical trial data readouts and the ability to secure non-dilutive or equity-based funding to sustain long-term R&D cycles.

Comparison to Industry Standards

• The company's use of a 2:1 ratio for RSU to stock option grants is a specific internal compensation strategy.
• The company benchmarks its executive compensation against a peer group of 18 publicly traded biotechnology companies, including Bicycle Therapeutics, IDEAYA Biosciences, and Relay Therapeutics.
• The company's clinical development milestones, such as the transition to pivotal trials, are standard benchmarks for late-stage clinical biotechnology firms.

Management Changes

Corporate Governance

Legal Proceedings

• None disclosed.

Related Party Transactions

• Consulting agreement with Malte Peters, M.D. in October 2025, which provided cash and equity compensation for services prior to his appointment as CEO.

Stakeholder Impact

• Shareholders are asked to vote on director elections and executive compensation.
• Employees and management are incentivized through equity awards and performance-based bonuses.
• Patients are the primary beneficiaries of the company's ongoing clinical development programs.

Next Steps

• Hold 2026 Annual Meeting of Stockholders on June 4, 2026.
• Initiate pivotal study for vopimetostat in 2026.
• Provide safety and efficacy updates for clinical trials in 2026.

Key Dates

Keywords

Tango Therapeutics, TNGX, Proxy Statement, Oncology, Biotechnology, Vopimetostat, Clinical Trials, Executive Compensation